Legalization and regulation updates, new research, industry moves and safety guidance — explained in plain language for curious minds.
A plain-language rundown of how research peptides are classified federally, where the provinces diverge, and what the latest guidance means for individuals. What's legal to possess, sell and import — and the grey areas still being tested.
Read the full story →As shortages ease, regulators are revisiting compounding rules. Here's what changes for suppliers and buyers.
An animal-model paper adds to the recovery literature. We break down what it does — and doesn't — show.
Two provinces updated their stance this quarter. A map of where things stand and what to watch next.
Fake certificates are getting slicker. The new checks that separate a real lab report from a forgery.
Supply is catching up with demand. What that likely means for per-mg pricing across suppliers.
A look at the expanding research questions around GLP-1 receptor agonists and what's still unproven.
Sample headlines shown for layout. Articles are illustrative placeholders and not legal or medical advice — always verify current laws in your region.
Share your experience or ask a question. For research discussion only — not medical advice.
